Catalyst Biosciences
CBIOCatalyst Biosciences in brief
Catalyst Biosciences is a listed company in the Biotechnology industry, based in the USA. Its market value was $637 M on 1 August 2026, which makes it the 11,516th largest listed company in the world and the 2,381st largest in the USA on this site. In the year to December 2025 it had sales of $117 M and a net profit of $10 M, about 8 cents of profit for every dollar of sales. Its shares trade under the symbol CBIO (Nasdaq).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
Market cap history
World rank over time
Rank in USA: #3,854 (Jan 2020) · #3,487 (Jan 2021) · #5,258 (Jan 2022) · #5,407 (Dec 2022) · #5,319 (Jul 2023) · #1,456 (Mar 2026) · #2,379 (Aug 2026)
Key ratios
- P/E ratio
- 64.5×
- Price / sales
- 5.5×
- Price / book
- 4.5×
- Free cash flow yield
- —
- Net margin
- 8.5%
- Operating margin
- 9.9%
- Return on equity
- 6.9%
- Liabilities / assets
- 14.4%
Annual results
- Revenue
- $117 M
- Operating income
- $11 M
- Net income
- $10 M
For year ending December-2025
Balance sheet
- Total assets
- $166 M
- Total liabilities
- $24 M
- Total equity
- $142 M
As of December-2025
Top 24 institutional investors in Catalyst Biosciences#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | Adage Capital Partners GP, L.L.C. | 1,800,000 | New | $18 M | Nov 16, 2026 |
| 2 | Linden Advisors LP | 1,300,000 | New | $13 M | Nov 16, 2026 |
| 3 | Tenor Capital Management Company, L.P. | 1,000,000 | New | $10 M | Nov 16, 2026 |
| 4 | Sculptor Capital LP | 879,997 | New | $9 M | Nov 13, 2026 |
| 5 | Shaolin Capital Management LLC | 700,000 | New | $7 M | Nov 13, 2026 |
| 6 | BNP Paribas Financial Markets | 681,794 | New | $7 M | Nov 12, 2026 |
| 7 | Polar Asset Management Partners Inc. | 600,000 | New | $6 M | Nov 16, 2026 |
| 8 | Verition Fund Management LLC | 557,664 | New | $5 M | Nov 13, 2026 |
| 9 | HBK Investments L P | 400,000 | New | $4 M | Nov 16, 2026 |
| 10 | Radcliffe Capital Management, L.P. | 400,000 | New | $4 M | Nov 16, 2026 |
| 11 | Two Sigma Investments, LP | 362,500 | New | $4 M | Nov 16, 2026 |
| 12 | Picton Mahoney Asset Management | 350,000 | New | $3 M | Nov 9, 2026 |
| 13 | Whitebox Advisors LLC | 325,000 | New | $3 M | Nov 16, 2026 |
| 14 | Berkley W R Corp | 321,691 | New | $3 M | Nov 16, 2026 |
| 15 | Hudson Bay Capital Management LP | 300,000 | New | $3 M | Nov 13, 2026 |
| 16 | O'Connor Alternative Investments, LLC | 300,000 | New | $3 M | Nov 16, 2026 |
| 17 | Ghisallo Capital Management LLC | 200,000 | New | $2 M | Nov 16, 2026 |
| 18 | Clear Street Group Inc. | 158,771 | New | $2 M | Nov 16, 2026 |
| 19 | Jpmorgan Chase & Co | 140,260 | New | $1 M | Nov 12, 2026 |
| 20 | K2 Principal Fund, L.P. | 109,902 | New | $1 M | Nov 13, 2026 |
| 21 | Toronto Dominion Bank | 100,000 | New | $1 M | Nov 16, 2026 |
| 22 | Virtu Financial LLC | 43,896 | New | $0 M | Nov 17, 2026 |
| 23 | Deltec Asset Management LLC | 30,000 | New | $0 M | Oct 26, 2026 |
| 24 | UBS Group AG | 5 | New | $0 M | Nov 10, 2026 |
Discuss Catalyst Biosciences#
0 automatic updates and 0 member comments. Sign in to comment and react.
No posts yet. Write the first comment.
How Catalyst Biosciences compares in Biotechnology
- Market cap$637 M · higher than 61% of 729
- Revenue$117 M · higher than 70% of 648
- Net margin8.5% · higher than 76% of 408
- P/E ratio64.5× · lower than 16% of 100
- Price / sales5.5× · lower than 60% of 340
- Price / book4.5× · lower than 34% of 535
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Catalyst Biosciences🇺🇸 | $637 M | 64.5× | 8.5% | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Autolus Therapeutics$641 M
- Arbutus Biopharma Corporation$644 M
- Wave Life Sciences Ltd.$625 M
- AgomAb Therapeutics NV$651 M
- CorMedix Inc.$652 M
- Sunmax Biotechnology Co., Ltd.$657 M
How current the figures are
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 22, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Catalyst Biosciences? Verify and update this profile — free
Show Catalyst Biosciences's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.